Blueprint Medicines price target raised to $84 from $80 at Stifel

Stifel raised the firm’s price target on Blueprint Medicines to $84 from $80 and keeps a Buy rating on the shares. The firm’s Ayvakit ISM prelaunch survey of 50 U.S. providers, including 30 hematologist/oncologists and 20 allergist/immunologists, increased its confidence in the sales opportunity and Blueprint’s ability to execute on the rare disease launch, the analyst tells investors. The firm maintains its "conservative" peak estimates until market data on access/reimbursement and treatment durations are captured, noting that it still models Ayvakit reaching over $1B sales after 2030.